Original Research
Feb 23
Jung-Hee Lee, Young Jin Youn, et al.
This study found that aspirin discontinuation within 1 month, followed by ticagrelor monotherapy, improved net clinical outcomes compared to 3-month discontinuation in patients with acute coronary syndrome undergoing percutaneous coronary intervention, primarily by reducing major bleeding without increasing ischemic risk.
State-of-the-Art
Feb 19
Asahi Oshima, Yoshinobu Onuma, et al.
This review summarizes the current evidence on lipid-lowering therapies, including statins, ezetimibe, bempedoic acid, and PCSK9 inhibitors, as well as the role of anti-inflammatory interventions in the management of atherosclerotic cardiovascular disease.
free
Consensus Document
Feb 19
Gabor G. Toth, Giulio Stefanini, et al.
This consensus statement provides guidance on patient selection, procedural considerations, and post-procedural management for day-case coronary procedures to facilitate their wide-scale adoption.
free
Original Research
Feb 18
Stefan Verheye, Johan Bennett, et al.
The PINNACLE-I trial demonstrated the safety and effectiveness of the Hertz Contact Intravascular Lithotripsy (HC-IVL) device in facilitating and optimizing coronary stent implantation in patients with calcified lesions.
open access
new issue
Feb 16
A State-of-the-Art on adjunctive pharmacological strategies for residual risk; a consensus statement on day-case PCI; aspirin discontinuation timing in ACS; 7-year outcomes in COMPARE-ABSORB; the PINNACLE-I trial; a novel spacer for tricuspid regurgitation treatment; news from PCR; and more
Viewpoint
Feb 16
Bernard Prendergast
PCR announces a new era, with an expanded educational mission and commitment to advancing interventional cardiology through education, research, and innovation under a new leadership team.
free
Research Correspondence
Feb 13
Róbert Bellavics, Zoltan Ruzsa, et al.
This study compared the safety and efficacy of two closure devices, StatSeal and TR Band, for distal foot artery access site closure in 150 patients undergoing lower-limb endovascular interventions. Both devices showed low access site complication rates.
Flashlight
Feb 17
Fabian Barbieri, Markus Reinthaler, et al.
An 81-year-old male patient with severe, functional tricuspid regurgitation underwent a novel transcutaneous implantation of a spacer device (Pivot Extend), resulting in a reduction in TR severity and improvement in right ventricular function.
open access
Original Research
Feb 11
Gilbert H.L. Tang, Michael J. Reardon, et al.
This single-arm study evaluated the 5-year outcomes of the early-generation Intrepid transapical transcatheter mitral valve replacement system in high-risk patients with symptomatic ≥moderate-severe mitral regurgitation, observing sustained mitral regurgitation reduction and durable valve performance among survivors.
Editorial
Feb 12
Marianna Adamo, Elisa Pezzola
The content discusses the use of transcatheter edge-to-edge repair (TEER) for the treatment of mitral regurgitation, with data on patient characteristics, outcomes, and safety profiles.
free
Original Research
Feb 10
Stefano Cannata, Azeem Latib, et al.
This study compared the outcomes of TAVI using the self-expanding Navitor and balloon-expandable SAPIEN 3 Ultra transcatheter heart valves in patients with small aortic annuli. The Navitor device showed better hemodynamic performance but higher rates of mild paravalvular leak and permanent pacemaker implantation.
Flashlight
Feb 9
Masakazu Yasuda, Gaku Nakazawa, et al.
A 71-year-old male with schizophrenia and chronic subdural hematoma underwent urgent TAVI using a 26 mm SAPIEN 3 valve via left subclavian access. Prosthesis-balloon alignment failure and balloon rupture occurred, requiring retrieval of the stuck prosthesis and delivery system via the left ventricular apex.
open access
Research Correspondence
Feb 9
Yingyang Geng, Lei Song, et al.
This retrospective study found that left-dominant patients undergoing PCI for left main disease had a higher risk of long-term adverse events, particularly target vessel revascularization, compared to non-left-dominant patients.
Research Correspondence
Feb 5
Tim Wittig, Sabine Steiner, et al.
The COMPARE trial found no significant difference in 5-year clinically driven target lesion revascularization rates between low-dose and high-dose paclitaxel-coated balloons for the treatment of femoropopliteal lesions in patients with lower limb peripheral artery disease.
